Financials

	2024	2025
Net sales	4.05Cr 4.64Cr 3.81Cr 3.47Cr 6.51Cr 444.87Cr 6.52Cr 46Cr 18Cr 226.62Cr 17Cr 17Cr 731.28Cr	4.11Cr 4.71Cr 3.87Cr 3.53Cr 6.61Cr 451.59Cr 6.62Cr 46Cr 18Cr 230.04Cr 18Cr 17Cr 742.31Cr
Net income	71.55L 82.06L 67.38L 61.37L 1.15Cr 79Cr 1.15Cr 8.07Cr 3.11Cr 40Cr 3.08Cr 3.01Cr 129.22Cr	47.82L 54.85L 45.04L 41.02L 76.91L 53Cr 77.01L 5.39Cr 2.08Cr 27Cr 2.06Cr 2.01Cr 86Cr
Net Debt	-1.73Cr -1.98Cr -1.62Cr -1.48Cr -2.77Cr -189.57Cr -2.78Cr -19Cr -7.5Cr -97Cr -7.43Cr -7.27Cr -311.62Cr	-2.1Cr -2.41Cr -1.98Cr -1.8Cr -3.38Cr -231.13Cr -3.39Cr -24Cr -9.14Cr -117.74Cr -9.06Cr -8.86Cr -379.93Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

25/08	Lotus Bakeries, the most expensive speculoos on the (stock) market in Europe
30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	7.57Cr 8.68Cr 7.13Cr 6.49Cr 12Cr 831.34Cr 12Cr 85Cr 33Cr 423.48Cr 33Cr 32Cr 1.37TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	5.46Cr 6.27Cr 5.14Cr 4.69Cr 8.78Cr 600.21Cr 8.8Cr 62Cr 24Cr 305.75Cr 24Cr 23Cr 986.62Cr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

25/08	Lotus Bakeries, the most expensive speculoos on the (stock) market in Europe
30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

26/08	Lotus Bakeries, de duurste speculoos op de Europese beurs
26/08	Lotus Bakeries, la galleta más cara de la bolsa europea
25/08	Lotus Bakeries: Der teuerste Spekulatius der europäischen Börse
25/08	Lotus Bakeries, le spéculoos le plus cher de la bourse européenne
10/04	Eurofins Cerep : annonce ses résultats 2025

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.59%	+2.73%	+1.03%	+28.74%	4.63TCr
IQVIA HOLDINGS INC.	+1.30%	+1.58%	+44.15%	+35.50%	4.39TCr
REVOLUTION MEDICINES, INC.	+0.95%	-6.02%	+342.72%	+532.41%	4.09TCr
BEONE MEDICINES AG	+4.23%	+3.35%	+9.35%	+94.73%	3.99TCr
CELLTRION, INC.	+1.11%	+1.45%	+11.52%	+45.96%	2.95TCr
MEDPACE HOLDINGS, INC.	+1.94%	+4.84%	+25.19%	+159.21%	1.71TCr
ASCENDIS PHARMA A/S	+0.37%	-10.32%	-	-	1.55TCr
EUROFINS SCIENTIFIC SE	+2.12%	+8.18%	+24.78%	+41.21%	1.52TCr
TEMPUS AI, INC.	+0.24%	+25.43%	-11.57%	-	1.4TCr
Average	+1.41%	+3.23%	+55.90%	+133.97%	2.92TCr
Weighted average by Cap.	+1.51%	+1.71%	+70.37%	+142.46%

End-of-day quote Euronext Paris
- ^EUR	-